Krishan Jethwa (@KrishanJethwa) ranks #11 among US gi cancer KOLs on X in 2026, by engagement from fellow physicians. 17 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: SANO, KEYNOTE975, KEYNOTE-937. CMS Open Payments lists no 2025 general payments.
At a Glance
- 3 posts naming a trial in 2026
- 3 trials discussed by name
- GI Cancer: US #11 · 17 physicians engaged
- Leading physician voice: #3 of 16 physicians on SANO
- CMS Open Payments lists no 2025 general payments.
This Month
What Krishan Jethwa has posted in the last 30 days. Updated November 10, 2026.
🔥 SANO 5-year results🔥 Esophagus cancer 👥 309 pts with cCR after nCRT 🔍 Surveillance vs surgery ✅ 5y OS: 50% vs 54% (HR 1.17) ⚠️ Distant mets: 46% vs 29% (P<.01) 💥 43% organ preservation Active surveillance remains a feasible strategy albeit we must recognize the DM risk despite no OS difference. Perhaps TNT, like D-FLOT ➡️CRT with subsequent AS for cCR may be an optimal next strategy to test. Improved response assessment strategies also needed #ESMO26
🚨 KEYNOTE-975: NEGATIVE🚨 703 pts with unresectable esophageal/GEJ cancer Pembro + dCRT vs dCRT ❌ EFS (PD-L1 CPS≥10): 15.2 vs 14.7m (HR 0.97) ❌ OS: 32.2 vs 35.0m (HR 1.00) Study stopped after EFS endpoint not met. #ESMO26 https://t.co/e4K5rKw4s5
Who Amplifies Krishan Jethwa
Physicians who reposted Krishan Jethwa’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| GI Cancer | #11 | — | 17 | 19 | Full ranking |
Trials Krishan Jethwa Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| SANO | 1 | #3 of 16 | Oct 23, 2026 |
| KEYNOTE975 | 1 | #6 of 12 | Oct 23, 2026 |
| KEYNOTE-937 | 1 | #10 of 12 | Jan 9, 2026 |
Krishan Jethwa on SANO
🔥 SANO 5-year results🔥 Esophagus cancer 👥 309 pts with cCR after nCRT 🔍 Surveillance vs surgery ✅ 5y OS: 50% vs 54% (HR 1.17) ⚠️ Distant mets: 46% vs 29% (P<.01) 💥 43% organ preservation Active surveillance remains a feasible strategy albeit we must recognize the DM risk despite no OS difference. Perhaps TNT, like D-FLOT ➡️CRT with subsequent AS for cCR may be an optimal next strategy to test. Improved response assessment strategies also needed #ESMO26
Krishan Jethwa on KEYNOTE975
🚨 KEYNOTE-975: NEGATIVE🚨 703 pts with unresectable esophageal/GEJ cancer Pembro + dCRT vs dCRT ❌ EFS (PD-L1 CPS≥10): 15.2 vs 14.7m (HR 0.97) ❌ OS: 32.2 vs 35.0m (HR 1.00) Study stopped after EFS endpoint not met. #ESMO26 https://t.co/e4K5rKw4s5
Krishan Jethwa on KEYNOTE-937
🚨KEYNOTE-937🚨 Resected or ablated early stage HCC 🔎Adjuvant Pembro vs Placebo 🛑No improvement in RFS and no suggestion of improvement in OS 🧐Findings similar to IMBrave050… more work needed to identify ways to improve outcomes #ASCOGI26 https://t.co/7L8O5ajvKe
Krishan Jethwa’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
🔥AGITG MASTERPLAN🔥 Borderline resectable or Locally advanced PDAC n=75 🔍Randomized 3m mFOLFIRINOX or Gem+nab-Paclitaxel alone +/- SBRT (40 Gy/5 fx) Primary endpoint: locoregional recurrence 🚨SBRT had improved: ✅12 m LRR: 20% vs. 50% ✅mOS 22m vs. 14 m #ESMO26 https://t.co/Y1L97YhT3J
🚨UNION Trial🚨 Locally advanced rectal cancer N=231 🔍Randomized 🔵Chemoradiation➡️2c CAPOX➡️TME➡️6c CAPOX 🟢SCRT➡️2c CAPOX + camrelizumab ➡️TME➡️6c CAPOX+ cam 🔥SCRT + chemo-IO demonstrated a whopping difference in EFS, 91% vs. 77%!!! #ESMO26 https://t.co/rQz7cbbpZx
🚨ARION PRODIGE 67🚨 Locally Advanced Esophagus Cancer (adeno or squam) n=112 Randomized CRT (50 Gy/25 Fx + FOLFOX) +/- concurrent and adjuvant durvalumab (total 12 m) No SS differences in: PFS 48% vs. 50% OS 68% vs. 75% #ESMO26 https://t.co/yDHzaOsCyB
Industry Payments
CMS Open Payments · 2025 general payments
$0 across 0 payments